
- Oncology NEWS International Vol 7 No 3
- Volume 7
- Issue 3
IGF-1 Identified as Possible Risk Factor For Prostate Cancer
BOSTON--Investigators at McGill University, the Harvard School of Public Health, and Brigham and Women’s Hospital have identified insulinlike growth factor-1 (IGF-1) as a possible high-risk factor for prostate cancer.
BOSTON--Investigators at McGill University, the Harvard School of Public Health, and Brigham and Womens Hospital have identified insulinlike growth factor-1 (IGF-1) as a possible high-risk factor for prostate cancer.
A comparison of blood samples from 152 men in the Physicians Health Study who developed prostate cancer and 152 controls who did not showed that the prostate cancer patients had higher
IGF-1 levels. The 25% of men with the highest IGF-1 levels were 4.3 times more likely to develop prostate cancer than the men with the lowest IGF-1 levels.
The blood samples were collected an average of 7 years prior to the mens prostate cancer diagnosis, suggesting that, in most instances, the men did not have prostate cancer at the time the samples were drawn. This further suggests that high concentrations of IGF-1 may be a causative factor in the development of prostate cancer rather than just a marker of the presence of the disease.
The findings were published in the January 23, 1998, issue of the journal Science.
Articles in this issue
over 27 years ago
ACS Takes Aim at Proposed Federal Tobacco Billsover 27 years ago
Loan Defaults Disqualify 1,402over 27 years ago
FDA Gives OK to Seven New Cancer Drugs in 1997over 27 years ago
HIA Chemo Promising in Colon Cancer Liver Metsover 27 years ago
Proposed Budget Spells ‘Good News’ for NCIover 27 years ago
Proposed Budget Has Extra Funds for FDA Teen Smoking Effortover 27 years ago
CRFA Awards 16 New Grants and Fellowshipsover 27 years ago
Cancer Pain Treatment Requires Clear Terminology About ‘Addiction’over 27 years ago
‘Staging’ of the Managed Care Market Is Crucialover 27 years ago
NCI, EPA Attempt to Resolve Differences Over Childhood CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































